Navigation Links
Carmel Pharma Introduces PhaSeal Secondary Set (C60)
Date:10/31/2009

New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs

Columbus, OH (Vocus) October 31, 2009 -- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.

For safety and ease of use, the non-vented Secondary Set offers the following features:

 
  • Drip chamber (20 drops/mL)
  • Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
  • Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
  • DEHP-free PVC tubing (40 in.)

For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.

PhaSeal is more than a system for the safe handling of hazardous drugs. It's the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the "Gold Standard" in safe handling, PhaSeal's airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.

The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children's in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today's clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Emily Frydendal at 614-318-2635 or emily.frydendal (at) carmelpharma (dot) com.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3140064.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
2. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
3. China Pharma Holdings, Inc. to Report Third Quarter 2009 Financial Results on November 12, 2009
4. Cardinal Health Foundation, The Ohio State University College of Pharmacy Join Forces to Prevent Prescription Medication Abuse
5. WuXi PharmaTech Schedules Third-Quarter 2009 Earnings Release
6. 5 Steps to Pharmaceutical Marketing Happiness
7. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
8. Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution
9. CVS/pharmacy Rewards Shoppers For Passing on Plastic Bags
10. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
11. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Carmel Pharma Introduces PhaSeal Secondary Set (C60) 
(Date:1/19/2017)... ... 2017 , ... Students interested in video can get a jump start on ... earn a $1,000 scholarship and have his or her video posted on the GenCure ... May 31, with the winner announced on June 9. , The competition is designed ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... For ... serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity ... (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, is ...
(Date:1/19/2017)... ... 2017 , ... For the second consecutive year, all five ... have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, Dr. Joshua ... by their peers for the 2017 list based on their exceptional patient care ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan 18, 2017 Research and Markets ... by Product, by End User - Global Opportunity Analysis and Industry Forecast, ... ... 2015 and is expected to reach $5,491 million by 2022, growing at ... North America was the leading regional market in global ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... company specializing in the development and commercialization of regenerative ... and organs, recently reported the Company,s operating results for ... As the Company described in its recent ... year of substantial accomplishments. The Company,s contract laboratory completed ...
Breaking Medicine Technology: